FDAnews
www.fdanews.com/articles/81301-cardiome-and-astellas-announce-results-from-af-trial

CARDIOME AND ASTELLAS ANNOUNCE RESULTS FROM AF TRIAL

September 30, 2005

Cardiome Pharma and its codevelopment partner Astellas Pharma announced results from ACT 3, their recently completed 276-patient atrial arrhythmia Phase III clinical study. The study achieved its primary endpoint, showing that of the 170 patients with recent-onset atrial fibrillation (AF), 52 percent of those receiving an IV dose of RSD1235 converted to normal heart rhythm, as compared to 4 percent of placebo patients. These percentages are identical to those reported in the first pivotal Phase III study, ACT 1.

The ACT 3 study data suggests that RSD1235 was generally well-tolerated in the targeted patient population. In the 30 day interval following drug administration, serious adverse events occurred in 13 percent of all placebo patients and 10 percent of all patients dosed with RSD1235. Potentially drug-related serious adverse events occurred in 1 percent of placebo patients and 2 percent of patients receiving RSD1235. There were no cases of drug-related "Torsades de Pointes", a well-characterized arrhythmia which is an occasional side effect of many current antiarrhythmic drugs.